Navamepent

Navamepent (RX-10045) is a synthetic analogue^[1] of the endogenous fatty acid resolvin E1, a member of the specialized pro-resolving mediators. Navamepent is presumed to act as an agonist of the CMKLR1 receptor in a manner similar to resolvin E1.

Navamepent

Clinical data
Other names	RX-10045
Identifiers
IUPAC name propan-2-yl (5S,8E,10E,12R)-5,12-dihydroxypentadeca-8,10-dien-6,14-diynoate
CAS Number	1251537-11-7
PubChem CID	46926878
IUPHAR/BPS	9463
ChemSpider	57490355
UNII	Q7789B8MWM
ChEMBL	ChEMBL5314965
Chemical and physical data
Formula	C18H24O4
Molar mass	304.386 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)OC(=O)CCC[C@@H](C#C/C=C/C=C/[C@@H](CC#C)O)O
InChI InChI=1S/C18H24O4/c1-4-10-16(19)11-7-5-6-8-12-17(20)13-9-14-18(21)22-15(2)3/h1,5-7,11,15-17,19-20H,9-10,13-14H2,2-3H3/b6-5+,11-7+/t16-,17-/m1/s1 Key:ZVOCIIHCJJEFRQ-BHXBHYJPSA-N

It was developed as a topical ophthalmic formulation to promote recovery from eye inflammation and advanced to Phase II clinical trials, but was not pursued further.^[2][3][4]